BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 30540582)

  • 1. Cell-based immunotherapy in gynecologic malignancies.
    Schaar B; Krishnan V; Tallapragada S; Chanana A; Dorigo O
    Curr Opin Obstet Gynecol; 2019 Feb; 31(1):43-48. PubMed ID: 30540582
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Engineered T Cell Therapy for Gynecologic Malignancies: Challenges and Opportunities.
    Xu Y; Jiang J; Wang Y; Wang W; Li H; Lai W; Zhou Z; Zhu W; Xiang Z; Wang Z; Zhu Z; Yu L; Huang X; Zheng H; Wu S
    Front Immunol; 2021; 12():725330. PubMed ID: 34386017
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reformation in chimeric antigen receptor based cancer immunotherapy: Redirecting natural killer cell.
    Lin C; Zhang J
    Biochim Biophys Acta Rev Cancer; 2018 Apr; 1869(2):200-215. PubMed ID: 29378229
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cell-based immunotherapy in gynecologic malignancies.
    Schaar B; Krishnan V; Tallapragada S; Dorigo O
    Curr Opin Obstet Gynecol; 2018 Feb; 30(1):23-30. PubMed ID: 29227304
    [TBL] [Abstract][Full Text] [Related]  

  • 5. T-cell target antigens across major gynecologic cancers.
    Rodriguez-Garcia A; Minutolo NG; Robinson JM; Powell DJ
    Gynecol Oncol; 2017 Jun; 145(3):426-435. PubMed ID: 28377094
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Off-the-shelf cell therapy with induced pluripotent stem cell-derived natural killer cells.
    Saetersmoen ML; Hammer Q; Valamehr B; Kaufman DS; Malmberg KJ
    Semin Immunopathol; 2019 Jan; 41(1):59-68. PubMed ID: 30361801
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Engineering CAR-T Cells for Improved Function Against Solid Tumors.
    Morgan MA; Schambach A
    Front Immunol; 2018; 9():2493. PubMed ID: 30420856
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chimeric Antigen Receptor Expressing Natural Killer Cells for the Immunotherapy of Cancer.
    Mehta RS; Rezvani K
    Front Immunol; 2018; 9():283. PubMed ID: 29497427
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cell-based immunotherapies in gynecologic cancers.
    Lang SM; Dorigo O
    Curr Opin Obstet Gynecol; 2022 Feb; 34(1):10-14. PubMed ID: 34967809
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cell-based immunotherapy in gynecologic malignancies.
    Kamat K; Krishnan V; Berek JS; Dorigo O
    Curr Opin Obstet Gynecol; 2021 Feb; 33(1):13-18. PubMed ID: 33278077
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CAR T Cells Releasing IL-18 Convert to T-Bet
    Chmielewski M; Abken H
    Cell Rep; 2017 Dec; 21(11):3205-3219. PubMed ID: 29241547
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hurdles of CAR-T cell-based cancer immunotherapy directed against solid tumors.
    Zhang BL; Qin DY; Mo ZM; Li Y; Wei W; Wang YS; Wang W; Wei YQ
    Sci China Life Sci; 2016 Apr; 59(4):340-8. PubMed ID: 26965525
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetically Engineered Natural Killer Cells as a Means for Adoptive Tumor Immunotherapy.
    Michen S; Temme A
    Crit Rev Immunol; 2016; 36(4):329-347. PubMed ID: 28322137
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The dual-functional capability of cytokine-induced killer cells and application in tumor immunology.
    Zhang Q; Liu XY; Zhang T; Zhang XF; Zhao L; Long F; Liu ZK; Wang EH
    Hum Immunol; 2015 May; 76(5):385-91. PubMed ID: 25305457
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Leveraging immunotherapy for the treatment of gynecologic cancers in the era of precision medicine.
    Zamarin D; Jazaeri AA
    Gynecol Oncol; 2016 Apr; 141(1):86-94. PubMed ID: 27016233
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospects for chimeric antigen receptor-modified T cell therapy for solid tumors.
    Zhang E; Gu J; Xu H
    Mol Cancer; 2018 Jan; 17(1):7. PubMed ID: 29329591
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chimeric Antigen Receptor T Cell Therapy: Challenges to Bench-to-Bedside Efficacy.
    Srivastava S; Riddell SR
    J Immunol; 2018 Jan; 200(2):459-468. PubMed ID: 29311388
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Challenges of cancer therapy with natural killer cells.
    Klingemann H
    Cytotherapy; 2015 Mar; 17(3):245-9. PubMed ID: 25533934
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Viral and Nonviral Engineering of Natural Killer Cells as Emerging Adoptive Cancer Immunotherapies.
    Matosevic S
    J Immunol Res; 2018; 2018():4054815. PubMed ID: 30306093
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chimeric antigen receptor-engineered T cells for liver cancers, progress and obstacles.
    Li K; Lan Y; Wang J; Liu L
    Tumour Biol; 2017 Mar; 39(3):1010428317692229. PubMed ID: 28347250
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.